Novo Nordisk ends legal proceedings against Hims & Hers
Nordisk has dropped its legal case against telehealth provider him and her for patent infringement, after the two companies agreed…
Eli Lilly and company
Eli Lilly Launches Program to Increase Employer Coverage of Obesity Drugs
Eli Lilly On Thursday it launched a new program designed to help more employers cover obesity medications in the U.S.,…
Why Novo Nordisk's expansion in Ireland is key to fighting Eli Lilly
Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capabilities to…
What's next for Novo Nordisk's anti-obesity drug CagriSema?
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
Novo Nordisk to cut US list prices for Wegovy and Ozempic by up to 50%
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, on February…
Eli Lilly launches anti-obesity drug Zepbound with one-month dosage
An Eli Lilly & Co. Zepbound injection pen placed in the Brooklyn borough of New York on March 28, 2024.…
Novo Nordisk Shares Fall as Weight Loss Drug Fails to Beat Eli Lilly
The Novo Nordisk A/S headquarters in Bagsvaerd, Denmark, on Wednesday, November 5, 2025. Nichlas Pollier | Bloomberg | fake images…
FDA Chief Marty Makary on GLP-1 Copies, Vaccines and China
U.S. Food and Drug Administration (FDA) Commissioner Marty Makary presents a study from The Lancet during an announcement of the…
Medicare coverage opens opportunity for 15 million patients
Nordisk Chief Executive Mike Doustdar said Wednesday that the company aims to recruit about 15 million new patients, at least…
Novo Nordisk sues Hims & Hers over compounded obesity drugs
Nordisk on Monday said he is suing an online telehealth provider him and her to mass market cheaper, unapproved copies…